Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA
AUSTIN, Texas, March 4, 2011 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, announced today that Gail Page, Vermillion's Chief Executive Officer, will be presenting at the Roth 23rd Annual OC Growth Stock Conference at the Ritz Carlton, Laguna Niguel in Dana Point, CA.
The presentation is scheduled for Monday, March 14, 2011 at 1:00 p.m. Pacific. The presentation will be web cast and is available through the investor relations section of our web site at http://www.vermillion.com.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found on the Web at www.vermillion.com.
OVA1™ is a qualitative serum test that combines the
results of five immunoassays into a single numerical score. It is
indicated for women who meet the following criteria: over age 18,
ovarian adnexal mass present for which surgery is planned, and not
yet referred to an oncologist. The test utilizes five
well-established biomarkers - Transthyretin (TT or prealbumin),
Apolipoprotein A-1 (Apo A-1), beta 2-Microglobulin (beta 2M),
Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) - and a
proprietary FDA-cleared software device to determine the likelihood
of malignancy in women with pelvic mass for whom surgery is
planned. OVA1™ is a trademark of Vermillion, Inc.
Additional information about OVA1™ can be found on the
Web at www.ova-1.com